Table 1. . Toxicities from PCV and temozolomide causing treatment cessations in Phase III studies of newly diagnosed anaplastic gliomas or glioblastoma.
| Result | Procarbazine, iomustine and vincristine | Temozolomide |
|---|---|---|
| Discontinued treatment | ||
| Toxicity (%) | 9–38 [11–13] | 0–8 [5,11] |
| Refusal (%) | 5–9 [12,13] | 4 [5] |
| Toxicity | ||
| Grade 3–4 (%) | 20–56 [11–13] | 4–14 [5,11] |
| Grade 5 (death) | 2 (of 148) [13] | 0 [5,11] |
| Treatment modifications | ||
| Dose reductions | 16 [11] | 6 [11] |
| Interruptions | ||
| Frequency (%) | 18 [11] | 6 [11] |
| Duration (median, days) | 14 [11] | 10 [11] |